BIOCYTOGEN PHARMACEUTICALS (BEIJING) CO., LTD.

Communiqués Biocytogen Pharmaceuticals (Beijing) Co., Ltd.

Actions

2315

CNE100005D27

Cours en clôture Hong Kong S.E. Autres places de cotation 00:00:00 13/06/2024			Varia. 5j.	Varia. 1 janv.
8,05 ^CNY	+0,25%		-5,52%	-32,80%

06/05	Biocytogen conclut un accord d'évaluation et de licence potentielle avec Biocopy pour des anticorps imitant le TCR	CI
26/04	Biocytogen Pharmaceuticals réduit ses pertes en 2023	MT

Communiqués

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Biocytogen Enters Collaboration with ABL Bio to Develop New Bispecific Antibody-Drug Conjugates	26/03	AQ
Biocytogen Launches RenBiologics, a Sub-Brand Focused on Out-Licensing Fully Human Antibodies for Therapeutic Development	24/01	AQ
Biocytogen Enters into Bispecific Antibody Drug Conjugate Agreement with Radiance Biopharma	09/01	AQ
Biocytogen and CtM Bio Achieve Milestone Progress in Co-Developing a TCR-mimic Antibody-based Multi-Specific T Cell Engager Targeting WT1/HLA-A02	28/12	AQ
Biocytogen Enters into Multi-Target Antibody Agreement with Neurocrine Biosciences	20/12	AQ
Biocytogen Pharmaceuticals (Beijing) signs antibody evaluation, option and license agreement with Ona Therapeutics	19/12	AQ
Biocytogen, Eucure Biopharma to Present Complete Clinical Data from YH003 Phase I Trial at ESMO 2023	17/10/23	AQ
Biocytogen Officially Launches RenMice Series	18/09/23	AQ
Biocytogen Establishes Two Business Divisions to Distinguish Preclinical Models and Services from Antibody Drug R&D	01/09/23	AQ
Biocytogen - Eucure and Syncromune Establish Technology Transfer Agreement for YH002 and Multiple Other Clinical-Stage Antibodies	31/08/23	AQ
Biocytogen Opens San Francisco Office to Accelerate Globalization	01/06/23	AQ
Biocytogen Announces RenLite Licensing Agreement with Janssen	09/03/23	AQ
Biocytogen's Subsidiary Eucure Biopharma and Chipscreen Biosciences Holding Subsidiary Chipscreen NewWay Biosciences Enter into Greater China License Agreement for Bispecific Antibody YH008	28/02/23	AQ
Biocytogen Launches 'Nano 100 Project' to Develop Fully Human Nanobody Therapeutics for Over 100 Targets	21/02/23	AQ
Biocytogen Launches RenNano Mouse, a Fully Human Heavy Chain Antibody Platform to Accelerate Nanobody Drug Discovery	30/12/22	AQ
Biocytogen Announces FDA Clearance of IND Application for Bispecific Antibody YH008	20/12/22	AQ
Eucure - First Patient Dosed in Phase 1/2 Trial Evaluating YH001 in Combination with Envafolimab and Doxorubicin in Front Line Sarcoma Patients	22/11/22	AQ
Eucure Biopharma, a Subsidiary of Biocytogen Pharmaceuticals, Licenses OX40 Antibody and Multiple Active Ingredients to Syncromune for the Development and Commercialization of Intratumoral Immunotherapy	18/10/22	AQ
Biocytogen to Present Progress of Preclinical and Clinical Assets at BIO-EUROPE 2022	18/10/22	AQ
Biocytogen to Present 12 Posters on Innovative Mouse and Rat Models	30/09/22	AQ

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Communiqués Biocytogen Pharmaceuticals (Beijing) Co., Ltd.

Actions

2315

CNE100005D27

Communiqués

Filtres